Singapore, July 24 -- Life Biosciences, a US-based biotechnology company pioneering cellular rejuvenation therapies to reverse and prevent multiple diseases of ageing, has announced the signing of a Memorandum of Understanding (MoU) with SingHealth Duke-NUS Regenerative Medicine Institute of Singapore (REMEDIS), a joint research institute under the auspices of the SingHealth Duke-NUS Academic Medical Centre, to continue to build out its therapeutic portfolio.

The REMEDIS collaboration will enhance Life Bio's growing R&D efforts to advance its cellular rejuvenation technology across age-related diseases by targeting multiple organ systems and will also continue to accelerate scientific capabilities in Singapore.

"Singapore is emerging as...